CRISPR Therapeutics was co-founded by Emmanuelle Charpentier in 2013. The company’s mission is "developing transformative gene-based medicines for serious human diseases." The commercial launch ...

In October, CRISPR Therapeutics co-founder Emmanuelle Charpentier and Intellia co-founder Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for their work on CRISP/Cas9. The importance of ...

Earlier this month Scribe Therapeutics, a developer of CRISPR-based genome and epigenome ... the 2020 Nobel Prize in Chemistry, shared with Emmanuelle Charpentier, PhD, of the Max Planck Institute ...

So when, in 2012, Jennifer Doudna and Emmanuelle Charpentier discovered CRISPR ... the best stocks to ride the incoming wave of commercialization of CRISPR-based therapies. CRISPR Therapeutics was ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs. For example, using ...